In short, we could see Gilead finally command a rich premium in 2015 due to its dominant positions in HCV and HIV, as well as its under-appreciated clinical pipeline. Source: Wall Street Journal Orexigen launches new diet pill Orexigen and its marketing partner Takeda are attempting to finally open up the massive weight loss market that their competitors, Arena Pharmaceuticals and VIVUS, have so far failed to capture with their respective diet pills. Despite tens of millions of severely obese potential patients within the U.S., Arena and VIVUS' FDA approved weight loss drugs, Belviq and Qsymia, will probably generate only about $100 million in combined sales this year. Orexigen's pill, Contrave, has two advantages over its competitors that are already paying dividends in terms of capturing market share. First, Contrave is the only FDA approved obesity drug with a large amount of data on cardiovascular outcomes.